Quantitative Measurement of Melanoma Spread in Sentinel Lymph Nodes and Survival

PLoS Medicine

Volumn 11, Issue 2, 2014, Pages

  Ulmer, Anja ^a   Dietz, Klaus ^a   Hodak, Isabelle ^b   Polzer, Bernhard ^b,c   Scheitler, Sebastian ^b   Yildiz, Murat ^b   Czyz, Zbigniew ^b,c   Lehnert, Petra ^a   Fehm, Tanja ^d   Hafner, Christian ^b   Schanz, Stefan ^a   Röcken, Martin ^a   Garbe, Claus ^a   Breuninger, Helmut ^a   Fierlbeck, Gerhard ^a   Klein, Christoph A ^b,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 100; MELAN A;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CELL DENSITY; CHILD; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CYTOLOGY; DISSEMINATED CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; QUANTITATIVE ANALYSIS; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; THEORY VALIDATION; ULCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; CHILD; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84895453041     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001604     Document Type: Article

References (35)

1. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, et al. (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127: 392-399.
2. Reintgen D, Cruse CW, Wells K, Berman C, Fenske N, et al. (1994) The orderly progression of melanoma nodal metastases. Ann Surg 220: 759-767.
3. Gershenwald JE, Soong SJ, Balch CM, (2010) 2010 TNM staging system for cutaneous melanoma.and beyond. Ann Surg Oncol 17: 1475-1477.
4. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199-6206.
5. Murali R, Desilva C, McCarthy SW, Thompson JF, Scolyer RA, (2012) Sentinel lymph nodes containing very small (<0.1 mm) deposits of metastatic melanoma cannot be safely regarded as tumor-negative. Ann Surg Oncol 19: 1089-1099.
6. van Akkooi AC, de Wilt JH, Verhoef C, Schmitz PI, van Geel AN, et al. (2006) Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 17: 1578-1585.
7. van der Ploeg AP, van Akkooi AC, Schmitz PI, Koljenovic S, Verhoef C, et al. (2010) EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam criteria. Eur J Cancer 46: 2414-2421.
8. van Diest PJ, (1999) Histopathological workup of sentinel lymph nodes: how much is enough? J Clin Pathol 52: 871-873.
9. Abrahamsen HN, Hamilton-Dutoit SJ, Larsen J, Steiniche T, (2004) Sentinel lymph nodes in malignant melanoma: extended histopathologic evaluation improves diagnostic precision. Cancer 100: 1683-1691.
10. Cochran AJ, Balda BR, Starz H, Bachter D, Krag DN, et al. (2000) The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer 89: 236-241.
11. Starz H, Balda BR, Kramer KU, Buchels H, Wang H, (2001) A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 91: 2110-2121.
12. Murali R, Thompson JF, Scolyer RA, (2010) Location of melanoma metastases in sentinel lymph nodes: what are the implications for histologic processing of sentinel lymph nodes in routine practice? Am J Surg Pathol 34: 127-129.
13. Bagaria SP, Faries MB, Morton DL, (2010) Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute. J Surg Oncol 101: 669-676.
14. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, et al. (2006) Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355: 1307-1317.
15. Prieto VG, Clark SH, (2002) Processing of sentinel lymph nodes for detection of metastatic melanoma. Ann Diagn Pathol 6: 257-264.
16. Scolyer RA, Murali R, McCarthy SW, Thompson JF, (2008) Pathologic examination of sentinel lymph nodes from melanoma patients. Semin Diagn Pathol 25: 100-111.
17. Ulmer A, Fischer JR, Schanz S, Sotlar K, Breuninger H, et al. (2005) Detection of melanoma cells displaying multiple genomic changes in histopathologically negative sentinel lymph nodes. Clin Cancer Res 11: 5425-5432.
18. Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, et al. (2002) Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360: 683-689.
19. Klein CA, Schmidt-Kittler O, Schardt JA, Pantel K, Speicher MR, et al. (1999) Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci U S A 96: 4494-4499.
20. Baudis M, Cleary ML, (2001) Progenetix.net: an online repository for molecular cytogenetic aberration data. Bioinformatics 17: 1228-1229.
21. Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data. Hoboken (New Jersey): Wiley. 321 p.
22. Schwarz G, (1978) Estimating the dimension of a model. Ann Statist 6: 461-464.
23. Harrell FE Jr, Lee KL, Mark DB, (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15: 361-387.
24. Otto E (1963) Nomography. New York: Macmillan.
25. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97: 1180-1184.
26. Machado SG, Robinson GA, (1994) A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments. Stat Med 13: 2289-2309.
27. Scheri RP, Essner R, Turner RR, Ye X, Morton DL, (2007) Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol 14: 2861-2866.
28. Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, et al. (2013) T-helper-1-cell cytokines drive cancer into senescence. Nature 494: 361-365.
29. Klein CA, (2011) Framework models of tumor dormancy from patient-derived observations. Curr Opin Genet Dev 21: 42-49.
30. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, et al. (2012) Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18: 883-891.
31. Prieto VG, (2012) Cutaneous melanocytic lesions: do not miss the invisible gorilla. Adv Anat Pathol 19: 263-269.
32. Riber-Hansen R, Nyengaard JR, Hamilton-Dutoit SJ, Steiniche T, (2009) The nodal location of metastases in melanoma sentinel lymph nodes. Am J Surg Pathol 33: 1522-1528.
33. Mocellin S, Hoon DS, Pilati P, Rossi CR, Nitti D, (2007) Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis. J Clin Oncol 25: 1588-1595.
34. Schilling D, Hennenlotter J, Sotlar K, Kuehs U, Senger E, et al. (2011) Quantification of tumor cell burden by analysis of single cell lymph node disaggregates in metastatic prostate cancer. Prostate 70: 1110-1118.
35. Czyz TZ, Hoffmann M, Schlimok G, Polzer B, Klein CA, (2004) Reliable single cell array CGH for clinical samples. PLoS ONE 9: e85907.